Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan;14(1):67-75.
doi: 10.1517/14728220903449251.

RhoGDI2 as a therapeutic target in cancer

Hee Jun Cho  1 , Kyoung Eun Baek, Jiyun Yoo
Affiliations
Review

RhoGDI2 as a therapeutic target in cancer

Hee Jun Cho et al. Expert Opin Ther Targets. 2010 Jan.

Abstract

Importance of the field: Rho GDP dissociation inhibitor 2 (RhoGDI2) has been identified as a regulator of Rho GTPases that play important roles in the development of numerous aspects of the malignant phenotype, including cell cycle progression, resistance to apoptotic stimuli, neovascularization, tumor cell motility, invasiveness, and metastasis. Although RhoGDI2 has been known to be expressed only in hematopoietic tissues, recent studies suggest that this protein is also aberrantly expressed in several human cancers and contributes to aggressive phenotypes, such as invasion and metastasis. Hence, RhoGDI2 appears to be a target of interest for therapeutic manipulation.

Areas covered in this review: Here, we summarize the role of RhoGDI2 in human cancers, specifically metastasis-related processes, and discuss its potential as a therapeutic target.

What the reader will gain: RhoGDI2 modulates the invasiveness and metastatic ability of cancer cells through regulation of Rac1 activity.

Take home message: RhoGDI2 may be a useful marker for tumor progression in human cancers, and interruption of the RhoGDI2-mediated cancer cell invasion and metastasis by an interfacial inhibitor may be a powerful therapeutic approach to cancer.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

  • PLK1 phosphorylates RhoGDI1 and promotes cancer cell migration and invasion.
    Lim J, Hwang YS, Yoon HR, Yoo J, Yoon SR, Jung H, Cho HJ, Lee HG. Lim J, et al. Cancer Cell Int. 2024 Feb 14;24(1):73. doi: 10.1186/s12935-024-03254-z. Cancer Cell Int. 2024. PMID: 38355643 Free PMC article.
  • CRIF1 deficiency suppresses endothelial cell migration via upregulation of RhoGDI2.
    Nagar H, Kim S, Lee I, Choi SJ, Piao S, Jeon BH, Shong M, Kim CS. Nagar H, et al. PLoS One. 2021 Aug 26;16(8):e0256646. doi: 10.1371/journal.pone.0256646. eCollection 2021. PLoS One. 2021. PMID: 34437633 Free PMC article.
  • The molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targets.
    Liu W, Kovacevic Z, Peng Z, Jin R, Wang P, Yue F, Zheng M, Huang ML, Jansson PJ, Richardson V, Kalinowski DS, Lane DJ, Merlot AM, Sahni S, Richardson DR. Liu W, et al. Oncotarget. 2015 Nov 3;6(34):35522-41. doi: 10.18632/oncotarget.5849. Oncotarget. 2015. PMID: 26431493 Free PMC article. Review.
  • KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
    Liu L, Cui J, Zhao Y, Liu X, Chen L, Xia Y, Wang Y, Chen S, Sun S, Shi B, Zou Y. Liu L, et al. Mol Cancer. 2021 May 18;20(1):77. doi: 10.1186/s12943-021-01369-9. Mol Cancer. 2021. PMID: 34006303 Free PMC article.
  • Antibodies against ARHGDIB are associated with long-term kidney graft loss.
    Kamburova EG, Gruijters ML, Kardol-Hoefnagel T, Wisse BW, Joosten I, Allebes WA, van der Meer A, Hilbrands LB, Baas MC, Spierings E, Hack CE, van Reekum FE, van Zuilen AD, Verhaar MC, Bots ML, Drop ACAD, Plaisier L, Melchers RCA, Seelen MAJ, Sanders JS, Hepkema BG, Lambeck AJA, Bungener LB, Roozendaal C, Tilanus MGJ, Voorter CE, Wieten L, van Duijnhoven EM, Gelens MACJ, Christiaans MHL, van Ittersum FJ, Nurmohamed SA, Lardy NM, Swelsen W, van der Pant KAMI, van der Weerd NC, Ten Berge IJM, Hoitsma A, van der Boog PJM, de Fijter JW, Betjes MGH, Heidt S, Roelen DL, Claas FH, Bemelman FJ, Otten HG. Kamburova EG, et al. Am J Transplant. 2019 Dec;19(12):3335-3344. doi: 10.1111/ajt.15493. Epub 2019 Jul 3. Am J Transplant. 2019. PMID: 31194283 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

Substances

LinkOut - more resources